Lupin's Generic Spiriva Launch Delayed As FDA Action Expected By August
Medisol Acquisition To Push Injectables Growth
Lupin has pushed the US launch for a generic to Boehringer’s blockbuster COPD drug Spiriva to September as FDA action is now expected “latest by August”. Meanwhile, an acquisition of Medisol in France and ANDA submissions in the US are part of an ongoing focus on injectables.
